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Abstract: We have earlier reported that -hydroxybutyric acid (GHB) disrupts the acquisition of spatial learning and 
memory in adolescent rats. GHB is known to interact with several neurotransmitter systems that have been implicated in 
cognitive functioning. The N-methyl-D-aspartate receptor (NR) -type of glutamate receptor is considered to be an impor-
tant target for spatial learning and memory. Molecular mechanisms governing the neuroadptations following repeated 
GHB treatment in adolecent rats remain unknown. We examined the role of NMDA receptor in adolescent GHB-induced 
cognitive deficit. Adolescent rats were administered with GHB on 6 consecutive days, and surface-expressed NMDA  
receptor subunits levels were measured. GHB significantly decreased NR1 levels in the frontal cortex. Adolescent GHB 
also significantly reduced cortical NR2A subunit levels. Our findings support the hypothesis that adolescent GHB-induced 
cogntive deficits are associated with neuroadaptations in glutamatergic transmission, particulaly NR functioning in the 
frontal cortex. 
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1. INTRODUCTION 
  -hydroxybutyric acid (GHB), a short-chain fatty acid 
found endogenously in the brain [1], rapidly crosses the 
blood brain barrier following systemic administration result-
ing in CNS mediated effects. GHB is known to induce short-
term anterograde amnesia in humans, [2-4], and this GHB-
induced amnesia is thought to play a prominent role in drug-
facilitated sexual assault [4-6]. Although GHB-induced 
memory impairments have been reported in humans rela-
tively few studies have looked at the effects of GHB on 
learning and memory in animals. In monkeys, GHB failed to 
have any effect on the go/no-go visual discrimination task 
[7]. Navarro and coworkers studied the effects of chronic 
low doses of GHB (5-100 mg/kg for 12 - 30 days) on the 
“hole-board” task performance in adult mice, and reported 
that working memory was significantly reduced in GHB-
treated mice compared to controls [8-10]. In adult rats, GHB 
has been shown to decrease operant behavior but not work-
ing memory [11]. Earlier, our laboratory has shown that re-
peated GHB exposure in adolescent rats significantly im-
paired the acquisition of spatial learning and memory [12]. 
  The precise mechanisms underlying GHB actions remain 
unclear, but evidence supports that GHB acts via several 
different receptors. Since subcellularly GHB is located 
within the presynaptic terminal, it is thought to act as a neu-
rotransmitter/neuromodulator [13-15]. GHB is known to 
bind with specific brain receptors that have a distinct ana-
tomical distribution pattern with high densities of [
3H]GHB 
binding sites in the hippocampus including dentate gyrus, 
frontal cortex, septum, nucleus accumbens and caudate-
putamen. Areas such as the cerebellum, hypothalamus, and  
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pons-medulla are almost devoid of any such binding [13-17]. 
GHB has also been shown to interact with the GABAB re-
ceptor [18]. 
  Glutamate signalling is thought to play a significant regu-
latory role in neurocognitive functioning. GHB has been 
shown to increase glutamate release, and GHB-induced glu-
tamate release can be blocked by NR antagonists [19, 20]. 
GHB–induced seizure can be suppressed by NMDA antago-
nists [21]. Pretreatment with competitive (CGP 43487) and 
non-competitive (MK-801 and ketamine) NMDA receptor 
antagonist dose dependently suppressed GHB-induced with-
drawal seizures. Since spatial learning and memory have 
been associated with the NMDA receptor, and GHB impairs 
the acquisition of this type of memory, we tested the   
hypothesis that GHB-induced memory deficit is associated 
with alterations in NMDA receptor functioning. 
2. MATERIALS AND METHODS 
2.1. Animals 
  Adolescent male Sprague-Dawley rats (Taconic, 
Germantown, MD), were used. Rats were housed in our 
temperature- and humidity-controlled animal care facility, 
with a 12 hr light\12 hr dark cycle and at a room temperature 
of 22°C. They were kept in plastic cages, three to a cage, 
with ad libitum access to food and water. Each rat was al-
lowed a minimum of 2-4 days to habituate to the colony be-
fore testing began. They were briefly handled each day dur-
ing this habituation process. All experimental protocols used 
were approved by the institutional Animal Review Commit-
tee, and were in compliance with the NIH Guide for the Care 
and Use of Laboratory Animals. 
2.2. Drug Treatment 
  Rats were randomly assigned to one of two groups – sa-
line, or GHB (100 mg/kg). All treatments were administered GHB–Induced Cognitive Deficits During Adolescence  Current Neuropharmacology, 2011, Vol. 9, No. 1    241 
daily by intraperitoneal (ip) injections for 6 consecutive 
days. Controls rats received isovolumetric ip saline injec-
tions at the same time. Fresh solutions of GHB were pre-
pared in physiological saline for each batch of rats. Drug 
solutions were refrigerated after injections, and warmed to 
room temperature prior to injections. Rats were sacrificed, 
and their brains removed. Frontal cortex was dissected and 
rapidly frozen on dry ice, and kept at -80°C until use. Differ-
ent sets of animals were used to measure the effects of re-
peated GHB treatment on NR binding and on NR subunit 
protein expression.  
2.3. [
3H] MK-801 Binding 
  Experimental protocols for synaptosomal membrane 
preparation and [
3H]MK-801 binding were as described be-
fore [12, 22]. On the day of membrane preparation, tissue 
samples were homogenized in 50 mM Tris-HCl and the ho-
mogenate was centrifuged for 15 min at 4°C. The pellet was 
suspended in Triton X-100 (0.04%) and incubated in a 37°C 
water bath for 20 min. Tris-HCl (100 mM) was added to the 
suspension, and centrifuged for 20 min. The supernatant was 
discarded and the pellet was resuspended in 50 mM Tris-
HCl. The homogenate was centrifuged and the pellet was 
washed three times. After the last spin the pellet was sus-
pended in 6 vol 0.32 M sucrose and stored at –80°C till 
needed. On the day of the binding experiment, the frozen 
Triton prep was thawed on ice and centrifuged for 15 min. 
The pellet was resuspended in 6 vol 5 mM Tris-acetate 
buffer and centrifuged for 20 min. The pellet was washed 
three times. The final pellet was suspended in Tris-acetate 
buffer. Two hundred and fifty μl of the membrane suspen-
sion was incubated with graded concentrations of [
3H]MK-
801 (0.5–30 nM) for 90 min, in the presence of 100 μM L-
glutamate and 100 μM glycine. Binding reaction was termi-
nated by rapid filtration under vacuum through GF/B filters 
presoaked in 0.1% polyethyleneimine. Filters were washed 
twice and radioactivity was measured by spectrophotometry. 
Protein concentrations in samples of membrane suspension 
were determined according to Peterson’s modification of 
Lowry’s method using the Sigma Protein Kit (Sigma, St. 
Louis, MO).  
2.4. Western Blotting for NR Proteins  
  Frozen brain regions were thawed, lysed in radioim-
munoprecipitation assay (RIPA) buffer (1X PBS, 1% NP-40, 
0.5% sodium deoxycholate, 0.1% SDS) containing protease 
inhibitor, and homogenized for 10 seconds on ice. The ho-
mogenate was transferred to an eppendorf tube and 0.1M 
PMSF (serine protease inhibitor) was added. The suspension 
was incubated on ice for 20 min, sonicated for 10 sec and 
then spun at 15,000xg for 10 min at 4°C. Supernatant was 
carefully collected without disturbing the pellet; pellet con-
tained nuclei and was discarded. Protein concentration in 
tissue lysate was measured using commercially available 
protein estimation kit (Pierce BCA Protein Assay kit, 
Thermo Fisher Scientific, Rockford, IL). Equal amounts of 
protein (40 g) from GHB-treated and control frontal corti-
ces were separated on 7.5% (w/v) SDS-PAGE electrophore-
sis. Following electrophoretic transfer of proteins onto nitro-
cellulose membrane (Trans Blot, Bio-Rad, Hercules, CA), 
membranes were incubated overnight with the primary
 
monoclonal antibody (NR1, NR2A, NR2B; 1:3000; BD Bio-
sciences, San Jose, CA) at 4°C. NR1 antibody detected all 
the NR1 splice variants. Blots were washed four times for 5 
min with the wash buffer, and then incubated with the sec-
ondary antibody (goat anti-mouse, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) diluted in wash buffer containing 5% 
(w/v) nonfat milk. Immunoreactive bands were visualized 
using ECL detection system (Perkin-Elmer, Waltham MA). 
Molecular weights were estimated using prestained protein 
standards (Rainbow molecular weight standard, Amersham).  
  Quantitation of western blots: To control for loading 
efficiency, blots were stripped and reprobed with -actin 
(Sigma). The immunoreactive bands were scanned and quan-
tified using a densitometric system (Bio-Rad GS-800 scan-
ner) and analyzed (BioRad Quantity One® Analysis 
Software, Hercules, CA). The densitometric volume for each 
band was calculated as the product of intensity (expressed in 
pixels) for the area of the band. The density values of the 
immunoreactive NR subunit bands were divided by the 
density values of the immunoreactive -actin bands from the 
corresponding gel lanes. Background correction values were 
subtracted from each lane to minimize the variability across 
membranes. 
2.5. Data Analysis and Statistics 
  For both radioligand binding and western blot analysis, 
3-6 independent experiments were performed. Average val-
ues from these experiments are reported as mean ± sem. 
Saturation binding experiments were analyzed using the 
Prizm
® curve-fitting and receptor binding analysis program 
(GraphPad, San Diego, CA). Saturation binding experiments 
were analyzed using the Prism
® curve-fitting and receptor 
binding analysis program (GraphPad, San Diego, CA). Sta-
tistical comparisons between each treatment group were car-
ried out using the student t test (p< 0.05). All statistical com-
parisons were performed using the Prism® software (Graph-
Pad, San Diego, CA). 
3. RESULTS 
3.1. Adolescent GHB Administration on [
3H]MK-801 
Binding 
 Saturation  [
3H]MK-801 binding experiments were car-
ried out in the frontal cortex of GHB-treated rats and saline 
controls. Scatchard plots were created to determine whether 
treatment effects involved changes in receptor affinity (Kd) 
and/or maximal binding. Under the binding conditions used a 
single binding site was detected. There were no differences 
in the Kd values between control and drug-treated brains. 
GHB treatment decreased [
3H]MK-801 binding to the 
NMDA receptor-channel complex.  
3.2. Adolescent GHB Administration on NR Subunit   
Levels 
  Changes in NMDA receptor subunit proteins following 
exposure to GHB were examined. To minimize the influence 
of sample-to-sample differences in quality and to control for 
errors in quantification or sample loading, NR1, NR2A and 
NR2B subunit levels were normalized to -actin expression 
in each sample. GHB treatment did not significantly influ-
ence  -actin-like immunoreactivity across all experiments. 
Both -actin-normalized NR1 and NR2A subunit levels were 242    Current Neuropharmacology, 2011, Vol. 9, No. 1  Sircar et al. 
significantly lower in GHB-treated brain compared to saline-
treated controls (Fig 1). Normalized NR2B subunit levels 
showed a tendency to increase in GHB-treated rats compared 
to saline-treated rats (1.05 ± 0.27 and 0.404 ± 0.11, respec-













Fig. (1). Repeated GHB administration alters the expression of the 
NR1 and NR2B receptor subunit proteins. NMDA receptor subunit 
protein expression was normalized to the apparent levels of b-actin 
in each sample. Compared to saline-treated controls, GHB decreased 
both NR1- and NR2A-like immunoreactivities in the frontal cortex. 
**p<0.01; *p<0.05 
DISCUSSION 
  Earlier we have reported that GHB impairs spatial learn-
ing and memory [12]. Here we report that GHB-induced 
memory impairments are associated with adaptive alterations 
in the excitatory glutamatergic system mediated by the 
NMDA receptor-gated ion channel. Repeated GHB admini-
stration decreased the maximal density of NMDA binding 
sites. There was a concomitant reduction in the levels of 
NR1 subunit as determined from the western blot studies. 
Levels of the NR2A subunit were also significantly lower  
in the frontal cortex of GHB administered rats compared   
to saline-treated controls. NR2B subunit levels appeared   
to be higher in GHB-treated rats than the saline-treated   
rats but the effect was not statistically significant. These 
findings suggest that some of the neuroadaptative changes 
following repeated GHB exposure are mediated by the 
NMDA receptor. 
  NMDA receptor is known to be crucial for mnemonic 
processes [23]. Repeated GHB administrations in adolescent 
rats resulted in decreased NR receptor binding along with a 
reduction in the levels of NR1 subunit, the constitutive 
NMDA receptor subunit. GHB has been reported to increase 
glutamate levels in the brain [19]. Increased excitatory amino 
acid levels in the brain following GHB exposure may be 
responsible for the down regulation of the NMDA receptor. 
Reduction in NR functioning as measured by [
3H]MK-801 
binding, has been reported for other drugs of abuse. Rats self 
administrating cocaine for seven days show significantly 
lower levels of NMDA receptor binding in the medial pre-
frontal cortex compared to saline-treated controls [2, 24].  
  Functional NMDA receptors are composed of the obliga-
tory NR1 subunit along with one or more members of the 
NR2 and/or NR3 subunit families. The presence of specific 
NR2 subunits significantly influences the pharmacological 
characteristics of the NMDA receptor. Since [
3H]MK-801, 
a functional marker of NMDA channel, was lower in 
GHB-treated frontal cortex compared to saline con-
trols, it is not surprising that the constitutive NR1 
subunit levels were also lower in the frontal cortex of 
GHB-treated rats than saline-treated rats. Rats treated 
with methamphetamine, another abused substance, have 
been shown to have lower NMDA receptor functioning as 
reflected by significant reductions in NR1 subunit expression 
in the frontal cortex [25].  
  It is interesting that the NR2A subunit protein levels were 
altered by repeated GHB exposure. NR2A subunit is thought 
to be important in synaptic plasticity, and in learning and 
memory. Mice lacking in NR2A receptor subunit (also re-
ferred to as GluR1) exhibit reduced long tem potentiation 
(LTP), as well as impairments in spatial learning and mem-
ory [26, 27]. NR2A subunit levels are reduced in animals 
exposed to lead during development, and this is associated 
with impairments in LTP [7].  
  Alterations in NR2B levels following adolescent GHB 
exposure did not reach statistical significance. Among the 
various NR subunits, the NR2B subunit expression is highly 
regulated during brain development. Normally it is the 
NR2B subunit that appears to be sensitive to drug exposure. 
One of the adaptive changes consistently seen following 
ethanol treatment is an upregulation of the NR2B subunit 
protein [28, 29]. 
  Together, the present study suggests that GHB exposure 
during adolescence results in adaptive regulations of the 
NMDA receptor system. Repeated GHB downregulates NR 
levels in the frontal cortex, and changes the heteromeric 
combination of the NMDA receptor subunits. Reduction in 
NR1/NR2A assembly appears to be sensitive to inhibition by 
GHB, and provides a mechanistic link to GHB-induced im-
pairments in spatial leaning and memory. 
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